Austral Capital

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, specializing in the research, development, and marketing of innovative anti-cancer drugs and therapies. Founded in 2010, the company focuses on solid tumor cancers and has developed proprietary technologies centered around long non-coding RNAs, specifically sense and antisense RNAs, which are synthesized in mitochondria and migrate to the nucleus. These nucleic acid-based therapeutics are designed to selectively induce apoptosis in cancer cells while sparing normal cells. Andes Biotechnologies is advancing its lead drug, Andes-1537, through clinical development under an active investigational new drug application in the United States. The company benefits from a strong management team, an extensive intellectual property portfolio, and collaborations with key stakeholders in the cancer research community.

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, specializing in the research, development, and marketing of innovative anti-cancer drugs and therapies. Founded in 2010, the company focuses on solid tumor cancers and has developed proprietary technologies centered around long non-coding RNAs, specifically sense and antisense RNAs, which are synthesized in mitochondria and migrate to the nucleus. These nucleic acid-based therapeutics are designed to selectively induce apoptosis in cancer cells while sparing normal cells. Andes Biotechnologies is advancing its lead drug, Andes-1537, through clinical development under an active investigational new drug application in the United States. The company benefits from a strong management team, an extensive intellectual property portfolio, and collaborations with key stakeholders in the cancer research community.

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, specializing in the research, development, and marketing of innovative anti-cancer drugs and therapies. Founded in 2010, the company focuses on solid tumor cancers and has developed proprietary technologies centered around long non-coding RNAs, specifically sense and antisense RNAs, which are synthesized in mitochondria and migrate to the nucleus. These nucleic acid-based therapeutics are designed to selectively induce apoptosis in cancer cells while sparing normal cells. Andes Biotechnologies is advancing its lead drug, Andes-1537, through clinical development under an active investigational new drug application in the United States. The company benefits from a strong management team, an extensive intellectual property portfolio, and collaborations with key stakeholders in the cancer research community.

Atakama Labs is a developer, publisher, and operator of social games, specializing in creating meaningful gaming experiences. The company focuses on producing games that aim to entertain while also making a positive impact on the world. Their offerings are primarily free to play, ensuring accessibility for a wide audience. Atakama Labs develops its games mainly in Chile and publishes them globally, either directly or through partnerships, depending on the specific platform and region. The company targets popular social platforms, including Facebook, Orkut, iOS, and Android, to reach its players.

Paperless Chile is a provider of electronic receipts and document management services in Latin America, specializing in the creation, processing, management, and custody of electronic documents. The company processes over two billion documents annually, catering primarily to global enterprise businesses. By offering standardized solutions for electronic invoicing, ballots, and contracts, Paperless enables companies to efficiently store and manage their data in a digital format. This service enhances operational efficiency and contributes to a more sustainable approach to document management.